Vanderbilt University Medical Center has been awarded a one-year, $34-million grant by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, to conduct a nationwide study of “convalescent plasma” as a treatment for COVID-19. The randomized, controlled trial will test whether infusions of plasma, the liquid part of blood collected from COVID-19 survivors, can help other hospitalized patients with COVID-19. The plasma contains antibodies against SARS-CoV-2, the virus that causes COVID-19.
The Critical Illness, Brain Dysfunction and Survivorship Center at Vanderbilt University Medical Center is following patients who have been hospitalized for COVID-19 over time to see if they develop long-term cognitive impairment, depression or post-traumatic stress disorder (PTSD). These disabling features suffered by millions of ICU survivors are called Post-Intensive Care Syndrome (PICS).
Vanderbilt University Medical Center is evaluating razuprotafib, a drug being investigated for the treatment of glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. “We urgently need to find effective treatments for COVID-19, especially for patients who develop severe lung injury from the virus,” said co-principal investigator Wesley Self, MD, an emergency medicine physician at Vanderbilt University Medical Center.
Vanderbilt University Medical Center investigators are leading a new study that examines the transmission of SARS-CoV-2, the virus that causes COVID-19, within households in Nashville. The study funded by the Centers for Disease Control and Prevention (CDC) aims to understand how fast the infections spread within households and the factors that may be associated with that transmission. This is one of few longitudinal studies in the country that will examine coronavirus infections among close contacts.
Early data assessing the primary language of those who received COVID-19 tests at Vanderbilt University Medical Center, and tested positive, illustrates the disproportionate impact the pandemic is having on racial or ethnic communities. Of the first 18,491 patients tested for the novel coronavirus, 1,063 speak 37 languages other than English, according to analysis of electronic health records by VUMC’s Office of Health Equity. Although this group represents 5.7% of those tested, they are 19.4% of those positive and the highest number reside in two adjacent Nashville ZIP codes.
Researchers at Vanderbilt University Medical Center are leading a nationwide study to determine the rate of novel coronavirus infection in U.S. children and their families. The study, named the HEROS (Human Epidemiology and Response to SARS-CoV-2) study and funded by the National Institute of Allergy and Infectious Diseases (NIAID), aims to gain insight into how many children ages 1 to 21 have been infected, the percentage of those infected who develop symptoms of COVID-19 and any differences in immune responses to the virus between children and adults within the same household.
Faced with a global pandemic of a virus previously unknown to humans, Vanderbilt University Medical Center (VUMC) is leading a clinical trial to understand if hydroxychloroquine, a well-known drug used for malaria and rheumatologic conditions, is safe and effective in treating hospitalized adults with COVID-19.